<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fructus mume (F. mume) has been used as a medicinal food in Japan and has been reported to have anti-inflammatory effects in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> and macrophage-mediated <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the effects of F. mume extracts on <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e> in rats with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> and the molecular mechanisms underlying these effects </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> was induced in male Wister rats by bilateral common <z:mp ids='MP_0006134'>artery occlusion</z:mp> (BCCAo) </plain></SENT>
<SENT sid="3" pm="."><plain>Daily administration of F. mume extracts was started on day 20 after post-BCCAo and continued for 40 days </plain></SENT>
<SENT sid="4" pm="."><plain>The status of hippocampus-dependent memory was evaluated in control rats, rats with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>, and rats with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> that were administered F. mume </plain></SENT>
<SENT sid="5" pm="."><plain>The levels of microglial activation were measured in the hippocampus and the fimbria of hippocampus, and expression levels of hippocampal <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) were examined </plain></SENT>
<SENT sid="6" pm="."><plain>Rats that received <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> showed spatial <z:hpo ids='HP_0002354'>memory impairments</z:hpo> relative to the control rats; these impairments were reduced by daily administration of F. mume </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of F. mume mitigated the microglial activation and alterations of hippocampal MAPK and NF-κB signaling in the rats with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>These results indicate that F. mume may possess therapeutic potential for the prevention of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> via inhibition of inflammatory processes </plain></SENT>
</text></document>